Replies to post #147640 on Biotech Values

[DewDiligence]

LLY—Pooled secondary analyses do not a regulatory success make. Thus, Solanezumab is almost certainly a no-go without new phase-3 studies, which is something LLY will wisely be reluctant to undertake.

[genisi]

LLY drug Solanezumab shows some signs of efficacy.

Guess that's why unlike the open-label extension study of bapineuzumab that was halted, for solanezumab:

An ongoing, open-label extension study, EXPEDITION-EXT, is fully enrolled and would continue as planned.